- Home
- SCSC vs GYRE Comparison
SCSC vs GYRE Comparison
Compare SCSC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCSC
- GYRE
- Stock Information
- Founded
- SCSC 1992
- GYRE 2002
- Country
- SCSC United States
- GYRE United States
- Employees
- SCSC N/A
- GYRE N/A
- Industry
- SCSC Retail: Computer Software & Peripheral Equipment
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SCSC Technology
- GYRE Health Care
- Exchange
- SCSC Nasdaq
- GYRE Nasdaq
- Market Cap
- SCSC 1.1B
- GYRE 1.1B
- IPO Year
- SCSC 1994
- GYRE N/A
- Fundamental
- Price
- SCSC $49.30
- GYRE $10.52
- Analyst Decision
- SCSC Hold
- GYRE
- Analyst Count
- SCSC 1
- GYRE 0
- Target Price
- SCSC N/A
- GYRE N/A
- AVG Volume (30 Days)
- SCSC 264.6K
- GYRE 132.7K
- Earning Date
- SCSC 02-04-2025
- GYRE 11-13-2024
- Dividend Yield
- SCSC N/A
- GYRE N/A
- EPS Growth
- SCSC N/A
- GYRE N/A
- EPS
- SCSC 3.14
- GYRE N/A
- Revenue
- SCSC $3,159,084,000.00
- GYRE $105,033,000.00
- Revenue This Year
- SCSC $2.58
- GYRE $25.32
- Revenue Next Year
- SCSC $4.90
- GYRE $12.95
- P/E Ratio
- SCSC $15.47
- GYRE N/A
- Revenue Growth
- SCSC N/A
- GYRE N/A
- 52 Week Low
- SCSC $31.01
- GYRE $8.26
- 52 Week High
- SCSC $53.90
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- SCSC 52.55
- GYRE 45.59
- Support Level
- SCSC $46.35
- GYRE $9.51
- Resistance Level
- SCSC $48.94
- GYRE $10.58
- Average True Range (ATR)
- SCSC 1.27
- GYRE 0.95
- MACD
- SCSC 0.04
- GYRE -0.10
- Stochastic Oscillator
- SCSC 91.90
- GYRE 20.57
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.